References
- McGeer, PL, Schul M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors in Alzheimer's disease: a review of 17 epidemiological studies. Neumlogy45, 425–432 (1996).
- Greenamyre JT, Maragos WF, Albin RL et al Glutamate transmission and toxicity in Alzheimer's disease. Frog: NeuropsychopharmacolPFhiatry12,165–204 (1988).
- Arias C, Arrieta I, Tapia R. Ab peptide fragment 25–35 potentiates the calcium dependent release of excitatory amino acids from depolarised hippocampal slices. Neurosci. Res. 41, 561–566 (1995).
- Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basilis of Meynert. Eur. j Phalmacol 293, 267–270 (1995).
- Leonard BE. Pharmacotherapy in the treatment of Alzheimer's disease: an update. World fiychiatry3(2), 84–88 (2004).
- Cockle SM, Kimber S, Hindmarch I. The effects of Ginkgo biloba extract (LI1370) supplementation on activities of daily living in free living older volunteers: a questionnaire survey. Hum. PFhopharmacol Gun. Exp. 15, 227–235 (2000).
- Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum. PFhopharmacol Clin. Exp. 16, 203–218 (2001).
- Voisin T, Reynish E, Portet F, Feldman H, Vellas B. What are the treatment options for patients with severe Alzheimer's disease? CNS Drugs 18, 575–583 (2004).
- Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H. The Bayer Activities of Daily Living Scale (B-ADL). Dement. Getiatr (27n. Disoirl. 9(Suppl.), 20–26 (1998).
- Reisberg B et al The Alzheimer's disease Activities of Daily Living International Scale (ADL-IS). Int. Psychogeriatrics 13(2), 163–181 (2002).
- Erzigkeit H, Lehfeld H, Pena-Casanova J et al The Bayer Activities of Daily living Scale: results from a validation study in three European countries. Dement. Geriatr Cogn. Disoirl 735, 1–17 (2001).